Abstract
Hydroxyproline is excreted in urine as a breakdown product of normal bone turnover: A dialyzable (D) fraction (90% of total) reflects active bone destruction and a nondialyazble (ND) fraction reflects bone growth/regrowth. In metastatic prostate cancer where blastic osseous metastases predominate, disease progression on bone scan correlated with elevation of both total hydroxyproline excretion (7.84 + 1.28, P < 0.001) and the ND urinary level (0.94 ± 0.20, P < 0.01). In patients with a serially stable/improving scan, urinary excretion of each fraction (2.18 + 0.27 and 0.27 ± 0.01) was similar to that of men with no evidence of disease. For Stage D2 prostate cancer, these two markers satisfactorily monitor osseous activity in the intervals between serial bone scintigraphy.
Original language | English (US) |
---|---|
Pages (from-to) | 117-121 |
Number of pages | 5 |
Journal | Cancer |
Volume | 53 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 1984 |
Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research